Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Development of a patient-reported outcomes symptom measure for patients with nontransfusion-dependent thalassemia (NTDT-PRO <sup>©</sup> )
Authors: Ali Taher
Vip Viprakasit
Maria Domenica Cappellini
Pranee Sutcharitchan
Richard Ward
Dalia Mahmoud
Abderrahmane Laadem
Anzalee Khan
Chad Gwaltney
Gale Harding
Kenneth Attie
Xiaosha Zhang
Jun Zou
Joseph Pariseau
X. Henry Hu
Antonis Kattamis
Evidera, USA
American University of Beirut Medical Center
Università degli Studi di Milano
Chulalongkorn University
Aghia Sophia Children's Hospital
Celgene Corporation
University of Toronto
Faculty of Medicine, Siriraj Hospital, Mahidol University
Nathan S. Kline Institute for Psychiatric Research
NeuroCog Trials
Acceleron Pharma
Keywords: Medicine
Issue Date: 1-Feb-2019
Citation: American Journal of Hematology. Vol.94, No.2 (2019), 171-176
Abstract: © 2018 The Authors. American Journal of Hematology published by Wiley Periodicals, Inc. β-Thalassemia, a hereditary blood disorder caused by reduced or absent synthesis of the β-globin chain of hemoglobin, is characterized by ineffective erythropoiesis, and can manifest as nontransfusion-dependent thalassemia (NTDT) or transfusion-dependent thalassemia (TDT). Many patients with NTDT develop a wide range of serious complications that affect survival and quality of life (QoL). Patient-reported outcomes (PRO), including health-related QoL (HRQoL), are important tools for determining patient health impairment and selecting appropriate treatment. However, there are currently no disease-specific PRO tools available to assess symptoms related to chronic anemia experienced by patients with NTDT. This study aimed to develop a new, US Food and Drug Administration (FDA)-compliant PRO of chronic anemia symptoms, the NTDT-PRO © tool, for use in patients with NTDT. Participants had a median age of 36 years (range, 18-47) and 60% were female. The initial development of the NTDT-PRO tool involved concept-elicitation interviews with 25 patients from 3 centers (in Lebanon, Greece, and Canada); subsequent interview discussions and clinical input resulted in the generation of 9 items for inclusion in the draft NTDT-PRO. Following a round of cognitive interviews involving 21 patients from 2 centers (in Lebanon and Greece), 4 items (Pain, Headaches, Ability to Concentrate, and Paleness) were removed from the draft NTDT-PRO. The final NTDT-PRO comprises 6 items that measure Tiredness, Weakness, and Shortness of Breath, with or without Physical Activity. The NTDT-PRO is a new disease-specific HRQoL tool for patients with NTDT, developed using a thorough methodology based on FDA 2009 PRO development guidelines.
ISSN: 10968652
Appears in Collections:Scopus 2019

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.